Bispecific T-cell engagers targeting GPRC5D, an orphan G protein–coupled receptor highly expressed in MM cells, (talquetamab) [85], and Fc receptor-homolog 5 (FcRH5), a type I membrane protein expressed on B cells, plasma cells, and nearly all MM cells, (cevostamab [BFCR4350A]) [86] are also being evaluated in phase 1 trials in MM in later lines of therapy. This evidence concerns the gene FCRL5 and Miyoshi myopathy.